The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy
- PMID: 37463049
- PMCID: PMC10471168
- DOI: 10.1172/JCI171554
The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy
Abstract
HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy (ART). The reservoir decays slowly over the first 7 years of ART (t1/2 = 44 months). However, whether decay continues with long-term ART is unclear. Recent integration site studies indicate gradual selection against inducible, intact proviruses, raising speculation that decades of ART might allow treatment interruption without viral rebound. Therefore, we measured the reservoir in 42 people on long-term ART (mean 22 years) using a quantitative viral outgrowth assay. After 7 years of ART, there was no long-term decrease in the frequency of inducible, replication-competent proviruses but rather an increase with an estimated doubling time of 23 years. Another reservoir assay, the intact proviral DNA assay, confirmed that reservoir decay with t1/2 of 44 months did not continue with long-term ART. The lack of decay reflected proliferation of infected cells. Most inducible, replication-competent viruses (79.8%) had env sequences identical to those of other isolates from the same sample. Thus, although integration site analysis indicates changes in reservoir composition, the proliferation of CD4+ T cells counteracts decay, maintaining the frequency of inducible, replication-competent proviruses at roughly constant levels over the long term. These results reinforce the need for lifelong ART.
Keywords: AIDS/HIV; Molecular biology; T cells; Virology.
Conflict of interest statement
Figures






References
-
- Hammer SM, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997;337(11):725–733. doi: 10.1056/NEJM199709113371101. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U24 AI143502/AI/NIAID NIH HHS/United States
- UM1 AI164561/AI/NIAID NIH HHS/United States
- UM1 AI164570/AI/NIAID NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- R01 AI028433/AI/NIAID NIH HHS/United States
- UM1 AI164556/AI/NIAID NIH HHS/United States
- DP5 OD031834/OD/NIH HHS/United States
- UM1 AI164566/AI/NIAID NIH HHS/United States
- UM1 AI126620/AI/NIAID NIH HHS/United States
- R01 OD011095/OD/NIH HHS/United States
- R01 AI152703/AI/NIAID NIH HHS/United States
- P30 AI094189/AI/NIAID NIH HHS/United States
- P01 AI169615/AI/NIAID NIH HHS/United States
- UM1 AI164560/AI/NIAID NIH HHS/United States